SCHEMBL48901

SCHEMBL48901

CC(=O)Cc1cc(Cl)cc(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.43
TPMT P51580 1/20 0.41
POLB P06746 1/20 0.38
TSHR P16473 1/20 0.38
P2RX7 Q99572 1/20 0.37
TACR1 P25103 2/20 0.37
ACLY P53396 1/20 0.36
CYP3A4 P08684 1/20 0.36
ANO1 Q5XXA6 1/20 0.36
CNR1 P21554 1/20 0.36
GRN P28799 1/20 0.36
SORT1 Q99523 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
CTBP2 P56545 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3475810 0.90 MEN1 (0.36) IDO1TPMTPOLBP2RX7TACR1
SCHEMBL11771738 0.84 TPMT (0.57) TPMTPOLBTSHRL3MBTL1ALDH1A1
SCHEMBL21102126 0.82 MARS1 (0.43) POLBCYP3A4CNR1L3MBTL1CTBP2
SCHEMBL30748416 0.81 ADRA1D (0.45) CNR1CTBP2
SCHEMBL21101913 0.80 MEN1 (0.34) TACR1CYP3A4ANO1CNR1GRN
SCHEMBL201554 0.79 CTBP2 (0.59) IDO1CYP3A4CTBP2ALDH1A1
SCHEMBL12704178 0.78 TPMT (0.42) IDO1TPMTTSHRP2RX7TACR1
SCHEMBL868125 0.78 CA2 (0.50) TPMTPOLBTSHRACLYALDH1A1
SCHEMBL12312513 0.77 TTR (0.45) POLBTSHRCYP3A4ALDH1A1
SCHEMBL13235717 0.77 ALDH1A1 (0.52) IDO1TPMTPOLBTSHRTACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2311818-B1 Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug NOVARTIS AG (CH) 2013-01-16 EP disclosed
US-8129541-B2 5-phenylthiazole derivatives and use as PI3 kinase inhibitors NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-1480962-B1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS NOVARTIS AG (CH) 2011-08-24 EP disclosed
EP-2311818-A1 Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug Novartis AG (CH) 2011-04-20 EP disclosed
US-20100093690-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS BRUCE IAN 2010-04-15 US disclosed
US-7687637-B2 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors NOVARTIS AG (CH) 2010-03-30 US disclosed
US-20050119320-A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors NOVARTIS AG (CH) 2005-06-02 US disclosed
EP-1480962-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS Novartis AG (CH) 2004-12-01 EP disclosed
WO-2003072557-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS NOVARTIS AG (CH) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093690-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS PIK3CA, PIK3R5, PIP5K1B IDO1 2810/4885TPMT 720/4885POLB 3369/4885
US-20050119320-A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors PIK3CA, PIK3R5, PIP5K1B IDO1 2810/4885TPMT 720/4885POLB 3369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.